Inotiv acquires genetic toxicology assets from milliporesigma's bioreliance® portfolio

West lafayette, ind., july 12, 2021 (globe newswire) -- inotiv, inc. (nasdaq:notv) (the “company”, “we”, “our” or “inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the company has acquired key genetic toxicology assets from milliporesigma's bioreliance® portfolio, including standard operating procedures, stock cultures, historic control data and client list. while inotiv did not disclose the specific financial terms, the transaction consists of a sales-based royalty agreement and does not require upfront funding from the company.
NOTV Ratings Summary
NOTV Quant Ranking